Coming into 2020, you might have expected the only really big story for VBI Vaccines (NASDAQ: VBIV) would be Sci-B-Vac, its hepatitis B vaccine. While the company has certainly achieved progress in that realm, investors' attention has focused largely on VBI's new vaccine candidate, which targets three types of coronavirus: SARS, MERS, and SARS-CoV-2 (the virus that causes COVID-19).
Both stories have translated into good news for VBI Vaccines this year. The biotech stock is up over 130% year to date in August (down from July, when it skyrocketed by as much as 347% over its January 2020 price). But is VBI Vaccines stock a buy now?
Image source: Getty Images.
Source Fool.com